A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Androgen-Independent Prostatic Cancer · Androgen-Independent Prostatic Neoplasms · Prostate Cancer Recurrent · Androgen-Insensitive Prostatic Cance · Androgen-Resistant Prostatic Cancer · Hormone Refractory Prostatic Cancer · Immunotherapy · Immune Checkpoint Inhibitor · Inhibitory Checkpoint Molecule
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 154 (final count)
- Started
- Sep 28, 2023
- Main results expected
- Feb 19, 2026
- Fully finished
- Mar 16, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Median radiographic progression free survival (rPFS) determined by investigator review.
Measured over: Every 9 weeks for the first year, followed by every 12 weeks for up to 3 more years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05848011 · record last updated 2026-05-22 · checked 2026-11-09 15:47 UTC